- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
March 22, 2023Benchmark Litigation Names Robins Kaplan 2023 Minnesota Law Firm of the Year
March 16, 2023Second Circuit Affirms Record $5.6 Billion Recovery in Antitrust Case
March 10, 2023Robins Kaplan Announces $28 Million Settlement in Case Against For-Profit College’s Directors & Officers
March 29-30, 2023ACI Managed Care Disputes and Litigation
April 3, 2023Conference of Tribal Lending Commissioners
April 11-13, 2023Mass Torts Made Perfect Seminar
March 13, 2023The Antitrust Case that Could Reshape Professional Golf
February 22, 2023A World Without Noncompetes: Protecting Confidential Information and Trade Secrets
February 7, 2023When Monkey Business Slips Into Trademark Infringement
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Kate Jaycox Appointed to Help Lead Zofran Litigation
December 30, 2015
In December 2015, the Honorable F. Dennis Saylor IV appointed Robins Kaplan LLP principal Kate Jaycox to the Plaintiffs’ Steering Committee for In Re: Zofran (ondansetron) Products Liability Litigation, MDL 2657. Judge Saylor was chosen to preside over the Zofran federal multi-district litigation (MDL) in October 2015.
Going forward, every claim filed in any federal court will automatically be transferred to the Zofran MDL in the District Court of Massachusetts, under the guidance of Judge Saylor. Ms. Jaycox is honored to help lead this litigation to try to obtain justice for the families and children affected by birth defects due to use of Zofran during pregnancy.
Several scientific studies have linked Zofran use during pregnancy to birth defects. For example, a 2012 study found that women who took Zofran were twice as likely to have a child with cleft palate.1 An August 2013 study surveying 897,000+ births in Denmark found a two-fold increased risk of heart defects in children of women who took Zofran during pregnancy, a risk which led to an overall 30% increased risk of major malformation.2
Robins Kaplan LLP is investigating cases in which a child was born with birth defects after the mother took Zofran during her first or early second trimester. We are investigating claims involving heart defects, cleft palette, cleft lip, as well as other birth defects. If you or someone you know has given birth to a child with a birth defect after taking Zofran during pregnancy and you wish to consult with a lawyer, please call us at 1-800-553-9910 or contact us.
1 Marlene Anderka et al., Medications Used to Treat Nausea and Vomiting of Pregnancy and the Risk of Selected Birth Defects 94(1) Birth Defects Res A Clin Mol Teratol 22 (2011).
2 JT Andersen et al., Ondansetron Use in Early Pregnancy and the Risk of Congenital Malformations – A Register Based Nationwide Control Study, presented at International Society of Pharmaco-epidemiology, Montreal, Canada (2013);
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.